MarginsXMarginsX
Home › Markets › Health Care › BLTE

Belite Bio Inc (BLTE)

BLTE trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$162.56
-1.09% on the day
Market cap
$6.5B
Mid cap
Revenue
Not reported in SEC XBRL data
Net income
Not reported in SEC XBRL data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerBLTE on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2022
SEC CIK0001889109
SEC industry codePharmaceutical Preparations
Incorporated inCayman Islands

Financials

Not reported in SEC XBRL data.

Warning signs

Cash runway
114.5 months
$352.9M cash at December 31, 2025
Share count, 1 year
+23.6%
2024-12-31 to 2025-12-31 · +58.0% over 3 years
Going-concern doubt
No
20-F filed March 31, 2026
Insider net buying, 12 months
-$40.5M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.20-F 2026-03-31
Cash and burn$352.9M cash; operating cash flow -$9.2M a quarter.Report 2025-12-31
Shares outstanding39,339,960 (2025-12-31); 31,826,549 a year earlier; 24,898,908 three years earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures.Cover page 2025-12-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the marketLatest 2025-12-02
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorDeloitte & Touche, Taipei, TaiwanPCAOB Form AP 2026-04-18
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $40.5M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-12-31
Not filed-$77.6M-$37.0M$352.9MNo debt tagsNeeds four quarters20-F 2026-03-31
FY 2024
2024-12-31
Not filed-$36.1M-$29.2M$31.7MNo debt tagsNeeds four quarters20-F 2026-03-31
FY 2023
2023-12-31
Not filed-$31.6M-$29.8M$88.2MNo debt tagsNeeds four quarters20-F 2026-03-31
FY 2022
2022-12-31
Not filed-$12.6M-$11.5M$42.1MNo debt tagsNeeds four quarters20-F 2025-03-17
FY 2021
2021-12-31
Not filed-$9.7M-$7.5M$17.3MNo debt tagsNeeds four quarters20-F 2024-03-12
FY 2020
2020-12-31
Not filed-$5.8M-$4.4M$25.6MNo debt tagsNeeds four quarters20-F 2023-03-31

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52025-12-02
Latest annual report20-F2026-03-31
Latest quarterly / interim
FORM 6-K
6-K2026-11-12

Source: SEC EDGAR submissions feed, 216 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+6.6%
1 month+8.2%
3 months-1.2%
Year to date+2.7%
1 year+46.2%
From 52-week high-15.1%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
ARWRArrowhead Pharmaceuticals Inc.$44.21-7.47%$6.2B
LGNDLigand Pharmaceuticals Incorporated$301.71-2.29%$6.0B
GRFSGrifols S.A.$8.73+0.46%$6.0B
SUPNSupernus Inc.$28.83-2.99%$6.0B
MIRMMirum Pharmaceuticals Inc.$91.58-2.56%$6.0B
AXSMAxsome Therapeutics Inc.$137.01-3.30%$7.2B
ABVXAbivax SA$83.61-4.53%$7.3B
AMRXAmneal Pharmaceuticals Inc.$21.23-0.70%$7.4B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier